Navigation Links
Sunitinib a Promising Agent for Treatment of Renal Cell Cancer

Sunitinib has been found to be an effective agent for treating metastatic renal cell cancer, a disease for which no effective treatment options are available so far//.

There is an urgent need for more active agents for the treatment of metastatic (spread of cancer from point of origin to another part of the body) renal cell carcinoma (RCC). The 5-year survival rate for metastatic RCC is estimated to be less than 10 percent, according to background information in the article. RCC is highly resistant to chemotherapy, and only a limited subset of patients (20 percent or less) benefit from cytokine (proteins from the immune system) therapy (high-dose interleukin-2 [IL-2] and/or interferon-alfa). Overall median survival following progression after cytokine therapy is approximately 10 to 13 months, and no effective treatment is available for patients whose disease progresses after an initial response, or who do not respond to cytokine therapy.

A better understanding of the genetic abnormalities associated with clear-cell RCC has helped identify new targets for therapy, and subsequently the development of a new therapy, the oral medication sunitinib, which had positive results in an initial study.

Robert J. Motzer, M.D., of Memorial Sloan-Kettering Cancer Center, New York, and colleagues conducted a multicenter phase 2 trial to confirm the antitumor efficacy of sunitinib in 106 patients with metastatic clear-cell RCC whose disease was refractory (unresponsive) to 1 prior cytokine therapy.

Patients were enrolled between February and November 2004, with follow-up continuing until disease progression, unacceptable toxicity, or withdrawal of consent. Patients received repeated 6-week cycles of sunitinib, 50 mg per day given orally for 4 consecutive weeks followed by 2 weeks off per treatment cycle.

“The results of this trial confirm that sunitinib given once daily according to a 4 weeks on/2 weeks off schedule has sub stantial antitumor effects against metastatic clear-cell RCC. Of the 105 evaluable patients, 36 patients achieved partial response (34 percent), and a median progression-free survival of 8.3 months as evaluated by the independent third-party core imaging laboratory (resulting in a value considerably longer than expected in this clinical setting),” the authors write.

The most common adverse events experienced by patients were fatigue 30 (28 percent) and diarrhea 21 (20 percent).

(Source: Newswise)
'"/>




Related medicine news :

1. Promising Treatment for Diabetes
2. Life after Bypass not so Promising for Women.
3. Promising cure for West Nile Virus
4. Deadly Diarrhoea Vaccine – Trail Results Promising
5. Novartis MS Drug Shows Promising Results
6. Promising Care Model For Bipolar Disorder
7. A Promising New Vaccination Strategy for Late-Stage Melanoma
8. Promising Brain Tumor Treatment In The Offing
9. Sea Creatures Toxin Could Lead to Promising Cancer Treatment
10. Vaccine Promising Against Hepatitis E
11. Groups Join Forces to Fund Promising Lung Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... ... May 24, 2016 , ... ... research and education, today announced that it has named Scott Santarella as its ... J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where he successfully helped ...
(Date:5/24/2016)... ... ... After graduating from Cornell, author Joshua Alexander was diagnosed with ... on Social Security disability and staying in a group home. In “ Healing Schizoaffective ... Balboa Press), Alexander shares how he was finally able to heal with the help ...
(Date:5/24/2016)... ... 2016 , ... PhysicianOne Urgent Care, advocators in helping their patients lead the ... avoid being bitten this spring. , The official tick season kicks off in ... are known for attaching themselves to their prey while they feed off their blood. ...
(Date:5/24/2016)... Lafayette, Colorado (PRWEB) , ... May 24, 2016 ... ... landscape architecture firm, announces the grand opening of ‘El Centro del Quinto Sol ... citizens of the Pueblo ‘east side’ community to offer something special for this ...
(Date:5/24/2016)... CA (PRWEB) , ... May 24, 2016 , ... ... cell imaging; high content imaging; multiplex immunoassays are widely used for cell and ... for labs to maximize their quality and efficiency in these areas. , LabRoots ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 2016 The World Health Organization (WHO) expanded the ... include adolescents aged 13 years, and above. Effective immediately, the ... adult and adolescent males in the 14 priority countries in ... the first male circumcision device to receive WHO Prequalification on ... Horowitz said: " The expanded use of ...
(Date:5/23/2016)... ABU DHABI , UAE, May 23, 2016 ... the importance of Precision Medicine and the role ...     The First International ... under the distinguished patronage and presence of Sheikh ... Development. The conference focused in Precision Medicine, which helps provide ...
(Date:5/23/2016)... -- The global  reprocessed medical devices market ... according to a new study by Grand View Research, ... the lack of centralized support for waste disposal in ... for reprocessed medical devices market. Additionally, the long-term cost-efficiency ... the original device is the high impact rendering driver ...
Breaking Medicine Technology: